Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05874635 · ClinicalTrials.gov registry record · NA

Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

A NA study of Diabetes Mellitus, Type 2 and Insulin Resistance, sponsored by Signos.

Active
Registry status
NA
Development phase
20,000
Enrollment target
1
Study location

NCT05874635 is a NA study of Diabetes Mellitus, Type 2 and Insulin Resistance that is active but no longer recruiting, run by Signos. The registered enrollment target is 20,000 participants, above the 4,428-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (352% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05874635, a NA study of Diabetes Mellitus, Type 2 and Insulin Resistance, is active but no longer recruiting, sponsored by Signos.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
20,000 participants
Enrollment target
1
Study location

Study Summary

The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools to help participants in the pursuit of weight change goals. We hypothesize that the use of CGM data and the Signos mHealth platform will assist with weight control in a population of people with type 2 diabetes mellitus who are not using insulin.

Interventions

  • DEVICE Continuous Glucose Monitor Device

Study Locations (1)

California

  • Signos - Palo Alto

Trial Details

FieldValue
Enrollment Target 20,000 participants
Start Date 2023-05-11
Est. Completion 2029-05-10
Phase NA

Sponsor

Signos

3 total trials

What the Registry Record Tells You About NCT05874635

The ClinicalTrials.gov registry entry for NCT05874635 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 20,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 4,428-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (352% higher). The listed sponsor is Signos, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Continuous Glucose Monitor Device is the first listed.

NCT05874635 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05874635 about?

NCT05874635 is a clinical study titled "Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)". The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools to help participants in...

What is the current status of trial NCT05874635?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 20,000 participants. The study started on 2023-05-11. Estimated completion is 2029-05-10.

What conditions does trial NCT05874635 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Insulin Resistance, Weight Loss, Metabolic Syndrome, Glucose Intolerance.

What interventions are being tested in trial NCT05874635?

The interventions under investigation include: Continuous Glucose Monitor Device (DEVICE).

Who is sponsoring clinical trial NCT05874635?

This trial is sponsored by Signos, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05874635 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.